Clinical Trial Update: Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating cabozantinib plus durvalumab with or without tremelimumab in patients with gastroesophageal cancer and other GI malignancies…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Esophageal Adenocarcinoma
• Gastric Cancer
• Hepatocellular Carcinoma

Drugs mentioned

• Cabometyx (cabozantinib)
• IMFINZI (DURVALUMAB)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Anwaar Saeed | Conditions: Gastric Cancer, Esophageal Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING